Floatz logo

Atirmociclib

Lung Adenocarcinoma

PfizerSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

67 Active assets in the Lung Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Anusha Kalbasi
Phase 2BBB
Carboplatin
Guangdong Association of Clinical Trials
Phase 3BBB
Nivolumab
Emory University
Phase 3BB
ETOPOSIDE
Guangdong Association of Clinical Trials
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Guangdong Association of Clinical Trials
Phase 3BB

View all 50 →

Same molecule, other indications

Atirmociclib is also rated in:

breast cancerDormant
B
Indicative ·
63 / 100
View asset →
breast cancerDormant
B
Indicative ·
59 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →